Will torcetrapib be the next big thing in coronary heart disease risk reduction?

Area of Science:

• Cardiovascular medicine
• Pharmacology
• Biochemistry

Background:

• Coronary heart disease (CHD) remains a leading cause of mortality.
• Increasing high-density lipoprotein (HDL) cholesterol is a therapeutic target for CHD.
• Cholesteryl ester transfer protein (CETP) plays a role in lipoprotein metabolism.

Purpose of the Study:

• To evaluate torcetrapib, a novel CETP inhibitor, as a strategy to increase HDL cholesterol.
• To assess the potential of torcetrapib in reducing atherosclerotic vascular disease.

Main Methods:

• Torcetrapib acts as a partial inhibitor of cholesteryl ester transfer protein (CETP).
• Mechanism involves retaining cholesteryl ester within HDL particles.
• Evidence from CETP deficiency studies, genetic polymorphisms, and animal models supports the approach.

Main Results:

• Torcetrapib effectively increases HDL cholesterol levels.
• The drug demonstrates efficacy both as monotherapy and in combination with atorvastatin.
• Torcetrapib appears to be well tolerated in initial assessments.

Conclusions:

• Torcetrapib shows promise in raising HDL cholesterol and potentially mitigating CHD.
• Further large-scale outcome trials are necessary to confirm its clinical benefit in reducing CHD.
• The drug's impact on atherosclerotic vascular disease requires definitive evaluation in ongoing survival studies.